Daewoong stock: Flodicitinib shows over 90% target occupancy in Phase 1
Published on 11/17/2026 at 02:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDaewoong advances autoimmune drug program
- Daewoong Pharmaceutical presented interim Phase 1 findings for oral flodicitinib at the American College of Rheumatology meeting.
- The company is conducting a multiple-dose study and targets completion of Phase 1 in the first quarter of next year.
Daewoong Pharmaceutical presented interim Phase 1 results for its oral autoimmune drug candidate flodicitinib on Tuesday, November 17, at ACR Convergence 2026 in Orlando, Florida. The findings showed a maximum target occupancy of more than 90 percent for the BTK and ITK proteins in a single-dose study involving 44 healthy adults, MoneyToday reported.
Early signal for autoimmune development
Flodicitinib, also known as DWP212525, is designed to selectively inhibit JAK3, ITK and BTK, proteins involved in immune-cell activity and T-cell and B-cell activation. Daewoong is assessing the candidate for conditions including rheumatoid arthritis, systemic lupus erythematosus and Sjogren syndrome.
The single ascending-dose part of the first-in-human trial produced no serious adverse events, while reported adverse events were mild. The results provide early pharmacokinetic and safety information, but further clinical studies are required to establish therapeutic efficacy in patients with autoimmune disease.
Next phase of testing under way
Daewoong has completed the single ascending-dose study and is conducting a multiple ascending-dose study. It aims to complete the Phase 1 program in the first quarter of next year, keeping additional clinical data as the next material milestone for the candidate.
The development update follows a strong third-quarter operating performance. Korea Biomedical Review reported that consolidated operating profit rose 25.4 percent year on year to 71.3 billion Korean won, supported by record Nabota exports. The report also said research and development spending increased 30.1 percent in the quarter.
Daewoong's pharmaceutical portfolio
Daewoong Pharmaceutical develops and sells prescription medicines, aesthetic products and over-the-counter drugs. Its portfolio includes the botulinum toxin product Nabota, the P-CAB treatment Fexuclue and digital healthcare activities, while its development pipeline covers autoimmune, respiratory and drug-delivery programs. The company is based in South Korea and is expanding selected products into international markets.
In the South Korean pharmaceutical market, Daewoong is a diversified developer and commercial operator rather than a single-product specialist. Its competitive position combines established commercial products such as Nabota and Fexuclue with new clinical programs, making execution in late-stage development and international commercialization important for investors.
Daewoong Pharmaceutical at a glance
- Company: Daewoong Pharmaceutical Co., Ltd.
- ISIN: KR7003090008
- Key development: Flodicitinib Phase 1
- Primary products: Nabota and Fexuclue
- Headquarters: South Korea
South Korea's pharmaceutical sector is the broader market setting for Daewoong; see Current market reports.
